|

|
home >
articles > parkinson's disease
Glutathione Articles - Parkinson's Disease
-
Sechi G; Deledda MG; Bua G;
Satta WM; Deiana GA; Pes GM; Rosati G,
Reduced intravenous
glutathione in the treatment of early Parkinson’s disease. Prog
Neurophyschopharmacol Biol Psychiatry, 20(7); 1159-70 1996 Oct.
-
Johannsen P; Velander G; Mai J;
Thorling EB; Dupont E, Glutathione peroxidase in early and advanced
Parkinson’s disease. J Neurol Neurosurg Psychiatry, 54 (8); 679-82
1991 Aug.
-
Spina MB; Cohen G,
Dopamine turnover and glutathione oxidation: implications for Parkinson’s
disease. Proc Natl Acad Sci U S A, 86(4); 1398-400 1989 Feb.
-
Di Monte DA; Chan P; Sandy MS,
Glutathione in Parkinson’s
disease: A link between oxidative stress
and mitochondrial damage? Ann Neurol. 1992 Suppl (32); S111-5.
-
Sian J; Dexter DT; Lees AJ;
Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD,
Alterations in
glutathione levels in Parkinson’s disease and other neurodegenerative
disorders affecting basal ganglia. Ann Neurol, 36(3); 348-55 1994
Sep.
-
Merad-Boudia M; Santiard-Baron
D; Saill’e C; Ceballos-Picot I,
Mitochondrial impairment as an early
event in the process of apoptosis induced by glutathione depletion in
neuronal cells: Relevance to Parkinson’s disease. Biochem
Pharmacol, 56(5):645-55 1998 Sep 1.
-
Perry TL; Yong V,
Idiopathic Parkinson's disease, progressive supranuclear palsy and
glutathione metabolism in substantia nigra of patients. Neurosci
Lett 1986; 67:269-74.
-
Perry TL; Hansen S; Jones K,
Brain amino acids and glutathione in progressive supranuclear palsy.
Neurology 1988; 38:943-6.
-
Riederer P; Sofic E; Rausch W;
Schmidt B; Reynolds G; Jellinger K; Youdim M,
Transition metals,
ferrentin, glutathione, and ascorbic acid in pakinsonian brains. J
Neurochem 1989; 52:515-520.
-
Pearce R; Owen S; Daniel S;
Jenner P; Marsden C, Alterations in the distribution of glutathione
in substantia nigra in Parkinson's disease. J Neural Transm 1997;
104:661-77.
-
Jenner P; Dexter D; Sian J;
Schapira A; Marsden C; Oxidative stress as a cause of nigral cell
death in Parkinson's disease and incidental lewy body disease. Ann
Neurol 1992; 32:S82-S87.
-
Perry TL; Godin D V; Hansen S;
Jones K, Parkinson's Disease: a disorder due to nigral cell
glutathione deficiency. Neurosci Lett 1982; 33:300-10.
-
Jha N; Jurma O; Lalli G; Liu X;
Pettus EH, et al, Glutathione Depletion in PC12 Results in Selective
Inhibition of Mitochondrial Complex I Activity. J Biol Chem. 2000
Aug; Vol 275(34):26096-101.
-
Sian J, Dexter DT, Lees AJ,
Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD.
Alterations in glutathione levels
in Parkinson's disease and other neurodegenerative disorders affecting
basal ganglia. Ann Neurol. 1994 Sep;36(3):348-55.
-
Chinta SJ, Kumar MJ, Hsu M,
Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK.
Glutathione Depletion Leads to
Symptoms of Parkinson's Disease in Mice. J Neurosci. 2007 Dec
19;27(51):13997-4006.
-
Jenner P,
Altered mitochondrial function,
iron metabolism and glutathione levels in Parkinson's disease.
Acta Neurol Scand Suppl. 1993;146:6-13.
-
S. Canals, M. J. Casarejos, S.
de Bernardo, E. RodrõÂguez-MartõÂn and M. A. Mena,
Glutathione depletion
switches nitric oxide neurotrophic effects to cell death in midbrain
cultures: implications for Parkinson's disease. J
Neurochem. (2001) 79, 1183-1195.
-
Jenner P,
What process
causes nigral cell death in Parkinson's disease?
Neurol Clin. 1992 May 10(2):387-403.
Video Testimony of Glutathione Use with
Parkinson's Patients
Watch a video produced by Dr.
David Perlmutter showing the before and after effects of IV glutathione on
Parkinson's patients. > See Benefits
of Glutathione
If you would like us to send
you abstracts of any of the articles listed above, please contact us by
phone or e-mail:
Caron Coats
|
 |